Unusual Pyrimidine Participation: Efficient Stereoselective Synthesis of Potent Dual Orexin Receptor Antagonist MK-6096-Reference-Cited by-同舟云学术

Unusual Pyrimidine Participation: Efficient Stereoselective Synthesis of Potent Dual Orexin Receptor Antagonist MK-6096

Published:2014-11-03 Issue:22 Volume:16 Page:5890-5893
ISSN:1523-7060
Container-title:Organic Letters
language:en
Short-container-title:Org. Lett.

Author:

Chung John Y. L.¹,Zhong Yong-Li¹,Maloney Kevin M.¹,Reamer Robert A.¹,Moore Jeffrey C.¹,Strotman Hallena¹,Kalinin Alexei²,Feng Ronnie²,Strotman Neil A.¹,Xiang Bangping¹,Yasuda Nobuyoshi¹

Affiliation:

1. Process Chemistry, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065, United States and

2. Chemical Process Development & Commercialization, Merck Manufacturing Division, P.O. Box 2000, Rahway, New Jersey 07065, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/ol5028249

Reference33 articles.

1. Sleep Complaints Among Elderly Persons: An Epidemiologic Study of Three Communities

2. Sleep Patterns and Mortality among Elderly Patients in a Geriatric Hospital

3. Insomnia in the Elderly: Cause, Approach, and Treatment

4. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transaminase catalyzed asymmetric synthesis of active pharmaceutical ingredients;Green Synthesis and Catalysis;2024-03

2. Considerations for the Scale‐up of in vitro Transaminase‐Catalyzed Asymmetric Synthesis of Chiral Amines;ChemCatChem;2023-06-15

3. Continuous flow-mode synthesis of (chiral) amines with transaminase: a strategic biocatalytic approach to essential building blocks;Reaction Chemistry & Engineering;2023

4. The Catalysis Laboratory at Merck: 20 Years of Catalyzing Innovation;ACS Catalysis;2022-12-20

5. Development of a Scalable Route with Efficient Stereoisomer Control to YZJ-1139, an Orexin Receptor Antagonist;Organic Process Research & Development;2022-01-27